News
ATRA
10.55
-5.47%
-0.61
Weekly Report: what happened at ATRA last week (0615-0619)?
Weekly Report · 2d ago
Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)
TipRanks · 3d ago
Atara Biotherapeutics director Brian Cherry files initial beneficial ownership statement
PUBT · 06/15 22:49
Spruce Biosciences names Eric Jordan as VP, Marketing
PUBT · 06/15 12:01
Weekly Report: what happened at ATRA last week (0608-0612)?
Weekly Report · 06/15 10:19
Atara Announces Departure Of Carol Gallagher As Director, Brian Cherry To Succeed
NASDAQ · 06/15 09:31
Atara Biotherapeutics Adds Independent Director to Board
TipRanks · 06/12 21:09
Atara Biotherapeutics names Brian Cherry to board of directors
PUBT · 06/12 20:00
ATARA BIOTHERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
Reuters · 06/12 20:00
Weekly Report: what happened at ATRA last week (0601-0605)?
Weekly Report · 06/08 10:15
Weekly Report: what happened at ATRA last week (0525-0529)?
Weekly Report · 06/01 10:19
Weekly Report: what happened at ATRA last week (0518-0522)?
Weekly Report · 05/25 10:22
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 05/22 16:00
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Barchart · 05/22 13:41
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
Barchart · 05/22 08:17
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
PR Newswire · 05/21 19:10
Top Atara Biotherapeutics Executives Quietly Cash Out in Latest Insider Moves
TipRanks · 05/21 02:07
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA
PR Newswire · 05/20 13:00
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Barchart · 05/20 11:00
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
PR Newswire · 05/19 13:00
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.